Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Marvel Biosciences Corp V.MRVL

Alternate Symbol(s):  MBCOF

Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:MRVL)

Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204

Newsfile March 25, 2024

Canadian biotech company reports positive autism treatment results

Jonathon Brown March 12, 2024

Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204

Newsfile March 12, 2024

Marvel Biosciences Announces Testing MB-204 on Autism by French University

Newsfile February 20, 2024

Marvel Biosciences Announces Closing of Non-Brokered Private Placement

Newsfile January 19, 2024

Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel

Newsfile January 8, 2024

Marvel Biosciences Invited to Test MB-204 on Autism by French University

Newsfile November 16, 2023

Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials

Newsfile August 22, 2023

Marvel Highlights Key Asset at the 2023 Alzheimer's Association International Conference

Newsfile July 10, 2023
View More News ››

Opinion & Analysis (TSXV:MRVL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:MRVL)

Marvel Biosciences Initiates Formulation Development

Calgary, Alberta--(Newsfile Corp. - April 6, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary...
Betteryear2 - April 6, 2022

Fox In The Hen House?

Check out the EHT forum and learn something.
suomynona - August 4, 2021
View more Bullboard ››

AM Resources Corp.

AM Resources Corp.

AM Resources Corporation is a Canada-based mining exploration company. The Company is a spodumene country play in Austria ...
View More »